Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Commentaries

Circulating microRNA Biomarkers of Diabetic Retinopathy

  1. Mugdha V. Joglekar1,
  2. Andrzej S. Januszewski2,
  3. Alicia J. Jenkins2 and
  4. Anandwardhan A. Hardikar1⇑
  1. 1Diabetes and Islet Biology Group, NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia
  2. 2Vascular Biology and Biomarker Laboratory, NHMRC Clinical Trials Centre, University of Sydney, Sydney, New South Wales, Australia
  1. Corresponding author: Anandwardhan A. Hardikar, anand.hardikar{at}ctc.usyd.edu.au.
Diabetes 2016 Jan; 65(1): 22-24. https://doi.org/10.2337/dbi15-0028
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

The incidence of diabetes is increasing globally, and in spite of modern treatments for glucose, blood pressure, and lipids, the vascular and neurologic complications of diabetes still occur at unacceptably high rates. The personal and economic burdens are enormous. Diabetes is a common cause for vision loss (diabetic retinopathy [DR]), renal impairment (nephropathy), peripheral and autonomic neuropathy and accelerated atherosclerosis leading to cardiovascular disease, cerebrovascular and peripheral vascular disease, and premature death (1). People with diabetes and with early renal damage are at particularly high risk of DR, renal failure, premature cardiovascular disease, and death. Moreover, people with DR are at increased risk of other micro- and macrovascular complications of diabetes (2). This may relate to common risk factors and mechanisms, such as damage to the vasculature, a chronic and clinically silent process. Vascular endothelial cells are the interface between blood and surrounding tissues, with key roles in regulation of inflammation, thrombosis, and angiogenesis and therefore a popular choice as a model for assessing endothelial damage and metabolic stress (3,4).

Vision loss due to DR is often preventable. However, for many people with diabetes it is often difficult to predict the clinical course of disease. Furthermore, not all people take or respond well to proven primary and secondary treatments for DR, including risk factor control, renin-angiotensin system drugs, fenofibrate, and late-stage treatments, such as ocular laser, corticosteroids, and anti–vascular endothelial growth factor agents. This highlights the importance of improving our understanding of the pathogenesis of DR and developing newer treatments and the necessity for clinical laboratory–based screening and monitoring tests (or panels thereof) that are highly sensitive and specific, widely available, and cost-effective for this potentially blinding condition. The field of oncology uses molecular markers in (clinical and basic) research and in clinical practice, but the use of such tools in diabetes is lacking. In this issue of Diabetes, the article by Zampetaki et al. (3) is an important advance in the field of microRNA (miRNA) biomarkers that has implications in the areas of disease (retinopathy) pathogenesis, prognostication, monitoring, and therapeutics.

miRNAs are a group of small (∼22 nucleotide) ubiquitously expressed RNA molecules that do not code for any protein but act posttranscriptionally to modulate expression of target genes via inhibition of protein expression by interfering with the translation and/or stability of mRNA. Cells release miRNAs into the circulation, where they have a long life span (approximately ≥2 weeks). Their stability in plasma/serum/urine on freeze-thawing, efficient recovery, and availability of quantitative detection methods enhances their use as a biomarker as well as a potential mediator of physiological and pathological processes. There is a paucity of miRNA clinical studies in DR, hence the importance of the study by Zampetaki et al. (3).

Zampetaki et al. (3) assessed 300 samples from two DR-related randomized, double-blind, parallel-design, and placebo-controlled clinical trials (PROTECT-1 and PREVENT-1). The authors assessed 155 baseline or DR progressors and 145 control samples (selected from 3,326 study participants) for a panel of 29 candidate miRNAs that were based on previous studies related to diabetes and myocardial infarction. They identified miR-27b and miR-320a as being significantly and independently associated with high DR risk. Complementing this analysis, they also elucidated the potential mechanism using cultured human endothelial cells and identified antiangiogenic thrombospondin-1 as a common target of these two miRNAs.

This study uses human clinical samples from existent DR trials, which is time-saving and cost-effective, and assays mature miRNAs on a robust gold-standard real-time PCR platform (5). The authors acknowledge the study strengths and most of its limitations. A weakness is the use of a candidate miRNA approach rather than an unprejudiced discovery (small RNA-sequencing) and validation approach. This is increasingly important as a single miRNA targets multiple (even hundreds) protein-coding gene transcripts, and candidate miRNAs important in diabetes or myocardial infarction may not be the best signature for DR. With regard to the cell culture studies, evaluation of other retinal cell types, cocultured retinal cells, and oscillating glucose concentrations in culture media, as occurs in vivo, would also have been of interest.

With regard to the statistical analysis, two complementary approaches, classical logistic regression (LR) and L1-penalized logistic regression (PLR), were used. Using LR for selecting markers from gene expression arrays can be prone to problems with multicollinearity and overfitting, but the results of LR are easy to present and interpret. PLR performs good model selection by shrinking the components of β to zero, effectively deleting these coefficients. For the PROTECT-1 arm, this method might have overestimated λ and contributed to the low DR predictive power (see Supplementary Fig. 5B in ref. 3). An alternate approach may be the use of Akaike information criterion to choose the λ value for PLR.

So far, there are few studies aimed at understanding the dysregulated miRNAs in DR, which we have summarized in Fig. 1. The majority use retinal tissues of various animal models or endothelial cells exposed to high glucose conditions in vitro (4,6–15). Very few studies have used clinical samples (3,5,16–18) or complementary clinical and basic science approaches, as Zampetaki et al. (3) did. We hope that this important report is followed by more clinical studies in which miRNAs are evaluated in larger study cohorts, across different ethnic groups, in different types of diabetes, and in a wide age range as well as different stages of DR. The effects of clinical, pharmacologic, and diabetes device–related interventions on miRNA profiles and their relationships to clinical end points are of great interest. It would also be of interest to see small RNA-sequencing analyses from such trials and to follow up these (or other identified) miRNAs in longitudinal studies to determine their predictive value for DR progression and responses to treatments. As miRNAs themselves may be therapeutic targets or even therapeutic agents (as anti-miRNAs) (15), further studies will help in identifying and assessing their therapeutic potential for the treatment of retinopathy in individuals with diabetes.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

Some of the important miRNAs from various studies attempting to identify dysregulated miRNAs in DR. The left panel shows miRNAs from in vitro experiments or animal models, and the right panel shows miRNAs reported from clinical studies. Commonly identified miRNAs are represented by intersecting circles. The background colors represent tissue sources for miRNA assessment. The lower panel shows miRNAs and their targets reported to be altered in DR. miR-200b (cyan-colored background) is currently being tested for therapeutic potential in DR. The predictive potential of these (or other) miRNAs will be revealed after careful assessment and validation in multiple clinical trials. EMT, endothelial to mesenchymal transition; E/PCs, endothelial or endothelial progenitor cells; HIF1α, hypoxia inducible factor-1α; MIAT, myocardial infarction–associated transcript; MMP9, matrix metalloproteinase-9, NFkB, nuclear factor-κB; Oxr1, oxidation resistance-1; SIRT1, sirtuin-1; VEGF, vascular endothelial growth factor.

Article Information

Funding. All authors are involved in the Fenofibrate And Microvascular Event Eye (FAME 1 EYE) study (2015-19), evaluating the protective effects of oral fenofibrate in (type 1 diabetes) DR over 5 years (led by A.J.J.), which is supported through JDRF and the National Health and Medical Research Council (NHMRC), Australia. All authors have performed microRNA biomarker analyses on samples from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study of oral fenofibrate in type 2 diabetes (led by A.C. Keech). A.A.H. is supported by the Australian Future Fellowship, Australian Research Council. M.V.J. has been supported through a post-doctoral fellowship from JDRF.

Duality of Interest. No potential conflicts of interest relevant to this article were reported.

Footnotes

  • See accompanying article, p. 216.

  • © 2016 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.

References

  1. ↵
    1. Barr EL,
    2. Zimmet PZ,
    3. Welborn TA, et al
    . Risk of cardiovascular and all-cause mortality in individuals with diabetes mellitus, impaired fasting glucose, and impaired glucose tolerance: the Australian Diabetes, Obesity, and Lifestyle Study (AusDiab). Circulation 2007;116:151–157pmid:17576864
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Kramer CK,
    2. Rodrigues TC,
    3. Canani LH,
    4. Gross JL,
    5. Azevedo MJ
    . Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes: meta-analysis of observational studies. Diabetes Care 2011;34:1238–1244pmid:21525504
    OpenUrlAbstract/FREE Full Text
  3. ↵
    Zampetaki A, Willeit P, Burr S, et al. Angiogenic microRNAs linked to incidence and progression of diabetic retinopathy in type 1 diabetes. Diabetes 2016;65:216–227
  4. ↵
    1. Mortuza R,
    2. Feng B,
    3. Chakrabarti S
    . miR-195 regulates SIRT1-mediated changes in diabetic retinopathy. Diabetologia 2014;57:1037–1046pmid:24570140
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    1. Farr RJ,
    2. Januszewski AS,
    3. Joglekar MV, et al
    . A comparative analysis of high-throughput platforms for validation of a circulating microRNA signature in diabetic retinopathy. Sci Rep 2015;5:10375pmid:26035063
    OpenUrlCrossRefPubMed
  6. ↵
    1. Yan B,
    2. Yao J,
    3. Liu JY, et al
    . lncRNA-MIAT regulates microvascular dysfunction by functioning as a competing endogenous RNA. Circ Res 2015;116:1143–1156pmid:25587098
    OpenUrlAbstract/FREE Full Text
    1. Cao Y,
    2. Feng B,
    3. Chen S,
    4. Chu Y,
    5. Chakrabarti S
    . Mechanisms of endothelial to mesenchymal transition in the retina in diabetes. Invest Ophthalmol Vis Sci 2014;55:7321–7331pmid:25335984
    OpenUrlAbstract/FREE Full Text
    1. Wu J,
    2. Wang R,
    3. Ye Z, et al
    . Protective effects of methane-rich saline on diabetic retinopathy via anti-inflammation in a streptozotocin-induced diabetic rat model. Biochem Biophys Res Commun 2015;466:155–161pmid:26363454
    OpenUrlCrossRefPubMed
    1. Takahashi Y,
    2. Chen Q,
    3. Rajala RV,
    4. Ma JX
    . MicroRNA-184 modulates canonical Wnt signaling through the regulation of frizzled-7 expression in the retina with ischemia-induced neovascularization. FEBS Lett 2015;589:1143–1149pmid:25796186
    OpenUrlCrossRefPubMed
    1. Ye P,
    2. Liu J,
    3. He F,
    4. Xu W,
    5. Yao K
    . Hypoxia-induced deregulation of miR-126 and its regulative effect on VEGF and MMP-9 expression. Int J Med Sci 2014;11:17–23pmid:24396282
    OpenUrlCrossRefPubMed
    1. Ling S,
    2. Birnbaum Y,
    3. Nanhwan MK,
    4. Thomas B,
    5. Bajaj M,
    6. Ye Y
    . MicroRNA-dependent cross-talk between VEGF and HIF1α in the diabetic retina. Cell Signal 2013;25:2840–2847pmid:24018047
    OpenUrlCrossRefPubMed
    1. Murray AR,
    2. Chen Q,
    3. Takahashi Y,
    4. Zhou KK,
    5. Park K,
    6. Ma JX
    . MicroRNA-200b downregulates oxidation resistance 1 (Oxr1) expression in the retina of type 1 diabetes model. Invest Ophthalmol Vis Sci 2013;54:1689–1697pmid:23404117
    OpenUrlAbstract/FREE Full Text
    1. Silva VA,
    2. Polesskaya A,
    3. Sousa TA, et al
    . Expression and cellular localization of microRNA-29b and RAX, an activator of the RNA-dependent protein kinase (PKR), in the retina of streptozotocin-induced diabetic rats. Mol Vis 2011;17:2228–2240pmid:21897745
    OpenUrlPubMed
    1. Kovacs B,
    2. Lumayag S,
    3. Cowan C,
    4. Xu S
    . MicroRNAs in early diabetic retinopathy in streptozotocin-induced diabetic rats. Invest Ophthalmol Vis Sci 2011;52:4402–4409pmid:21498619
    OpenUrlAbstract/FREE Full Text
  7. ↵
    1. McArthur K,
    2. Feng B,
    3. Wu Y,
    4. Chen S,
    5. Chakrabarti S
    . MicroRNA-200b regulates vascular endothelial growth factor-mediated alterations in diabetic retinopathy. Diabetes 2011;60:1314–1323pmid:21357793
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. García de la Torre N,
    2. Fernández-Durango R,
    3. Gómez R, et al
    . Expression of angiogenic microRNAs in endothelial progenitor cells from type 1 diabetic patients with and without diabetic retinopathy. Invest Ophthalmol Vis Sci 2015;56:4090–4098pmid:26114486
    OpenUrlCrossRefPubMed
    1. Hirota K,
    2. Keino H,
    3. Inoue M,
    4. Ishida H,
    5. Hirakata A
    . Comparisons of microRNA expression profiles in vitreous humor between eyes with macular hole and eyes with proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2015;253:335–342pmid:24970617
    OpenUrlCrossRefPubMed
  9. ↵
    1. Qing S,
    2. Yuan S,
    3. Yun C, et al
    . Serum miRNA biomarkers serve as a fingerprint for proliferative diabetic retinopathy. Cell Physiol Biochem 2014;34:1733–1740pmid:25427542
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Diabetes: 65 (1)

In this Issue

January 2016, 65(1)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by Author
  • Masthead (PDF)
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Circulating microRNA Biomarkers of Diabetic Retinopathy
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Circulating microRNA Biomarkers of Diabetic Retinopathy
Mugdha V. Joglekar, Andrzej S. Januszewski, Alicia J. Jenkins, Anandwardhan A. Hardikar
Diabetes Jan 2016, 65 (1) 22-24; DOI: 10.2337/dbi15-0028

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Circulating microRNA Biomarkers of Diabetic Retinopathy
Mugdha V. Joglekar, Andrzej S. Januszewski, Alicia J. Jenkins, Anandwardhan A. Hardikar
Diabetes Jan 2016, 65 (1) 22-24; DOI: 10.2337/dbi15-0028
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Article Information
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Adipose Tissue Malfunction Drives Metabolic Dysfunction in Alström Syndrome
  • Staying Connected: Transcriptomics in the Search for Novel Diabetic Kidney Disease Treatments
  • Going in Early: Hypoxia as a Target for Kidney Disease Prevention in Diabetes?
Show more Commentaries

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.